Links

Classifications

C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Abstract

A substantially pure or isolated oligodeoxynucleotide of at least 10 nucleotides is disclosed, wherein the oligodeoxynucleotide comprised a sequence represented by either formula:
5′ N1N2N3T-CpG-WN4N5N6 3′
wherein the CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are nucleotides, or the formula:
5′ RY-CpG-RY 3′
wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacological composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host. In some embodiments, the oligodeoxynucleotide includes the nucleic acid sequences set forth as SEQ ID NO: 137.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

This is a continuation of U.S. patent application Ser. No. 13/220,497, filed on Aug. 29, 2011, issued as U.S. Pat. No. 8,389,495, which is a continuation of U.S. patent application Ser. No. 11/595,211, filed Nov. 9, 2006, issued as U.S. Pat. No. 8,030,285, which is divisional of U.S. patent application Ser. No. 09/958,713, filed Oct. 7, 2002, abandoned, which is the §371 U.S. national stage of International Application No. PCT/US00/09839, filed Apr. 12, 2000, which was published in English under PCT Article 21(2), which in turn claims the benefit of U.S. Provisional Application 60/128,898, filed Apr. 12, 1999. The prior applications are incorporated by reference herein in their entirety.

TECHNICAL FIELD OF THE INVENTION

The present invention relates generally to induction of an immune response using specific oligodeoxynucleotides (ODNs).

Although bacterial DNA and certain ODNs can induce a murine immune response, little is known about the immunostimulatory capacity of these materials for the human immune system. Z. K. Ballas et al., 157 J. Immun. 1840 (1996). Differences in the responsiveness of human and murine B cells to certain stimuli render it impossible to extrapolate results obtained from mouse to man.

In view of the above, there exists a need for ODNs that induce an immune response in humans. In addition, there is a need for methods utilizing ODNs in the treatment of human diseases. The present invention provides such ODNs and methods of use. These and other advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.

BRIEF SUMMARY OF THE INVENTION

The present invention provides a substantially pure or isolated ODN of at least about 10 nucleotides comprising a sequence represented by either the formula:
5′ N1N2N3T-CpG-WN4N5N6 3′
wherein the central CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are any nucleotides, or the formula:
5′ RY-CpG-RY 3′
wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T. The present invention also provides an ODN delivery complex and pharmacological composition comprising the present inventive ODN, as well as a method of inducing an immune response by administering the present inventive ODN to a host.

SEQUENCE LISTING

The Sequence Listing is submitted as an ASCII text file 4239-62001-04_Sequence_Listing.txt, Feb. 5, 2013, 27.3, KB], which is incorporated by reference herein.

DETAILED DESCRIPTION OF THE INVENTION

Oligodeoxynucleotide

The present invention provides novel ODNs. These ODNs have at least about 10 nucleotides and comprise a sequence represented by either the formula:
5′ N1N2N3T-CpG-WN4N5N6 3′
wherein the central CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are any nucleotides, or the formula:
5′ RY-CpG-RY 3′
wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T. For example, the ODN can be selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 99.

Preferably, the ODN of the present invention is substantially pure or isolated. “Substantially pure” refers to an ODN that is substantially free of other materials, particularly other nucleic acids, proteins, lipids, carbohydrates, and other materials with which it may be naturally associated, while “isolated” refers to an ODN that is removed from its natural environment or state. Preferably, the ODN of the present invention consists of about 100 nucleotides or less (e.g., about 10-75 nucleotides). More preferably, the ODN consists of about 50 nucleotides or less (e.g., about 10-40 nucleotides). Even more preferably, the ODN consists of about 30 nucleotides or less (e.g., about 10-20 nucleotides). Most preferably the ODN consists of about 12 to about 16 nucleotides.

Any suitable modification can be used in the present invention to render the ODN resistant to degradation in vivo (e.g., via an exo or endonuclease). Preferably, the modification includes a phosphorothioate modification. The phosphorothioate modifications can occur at either termini, e.g., the last two or three 5′ and/or 3′ nucleotides can be liked with phosphorothioate bonds. The ODN also can be modified to contain a secondary structure (e.g., stem loop structure) such that it is resistant to degradation. Another modification that renders the ODN less susceptible to degradation is the inclusion of nontraditional bases such as inosine and quesine, as well as acetyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine. Other modified nucleotides include nonionic DNA analogs, such as alkyl or aryl phosphonates (i.e., the charged phosphonate oxygen is replaced with an alkyl or aryl group, as set forth in U.S. Pat. No. 4,469,863), phosphodiesters and alkylphosphotriesters (i.e., the charged oxygen moiety is alkylated, as set forth in U.S. Pat. No. 5,023,243 and European Patent No. 0 092 574). ODNs containing a diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini, have also been shown to be more resistant to degradation.

Preferably, the ODNs inducing a humoral immune response, e.g., 5′ N1N2N3T-CpG-WN4N5N6 3′, contain a phosphate backbone modification, and more preferably, the phosphate backbone modification is a phosphorothioate backbone modification (i.e., one of the non-bridging oxygens is replaced with sulfur, as set forth in International Patent Application WO 95/26204). For the ODNs inducing a cell-mediated immune response and containing a phosphodiester backbone, e.g., 5′ RY-CpG-RY 3′, the ODN preferably has been modified to prevent degradation.

Oligodeoxynucleotide Delivery Complex

The present inventive oligodeoxynucleotide delivery complex comprises the present inventive ODN and a targeting means. Any suitable targeting means can be used within the context of the present invention.

An ODN can be associated with (e.g., ionically or covalently bound to, or encapsulated within) a targeting means (e.g., a molecule that results in higher affinity binding to a target cell, such as a B cell). A variety of coupling or cross-linking agents can be used to form the delivery complex, such as protein A, carbodiamide, and N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP). Examples of ODN delivery complexes include ODNs associated with a sterol (e.g., cholesterol), a lipid (e.g., a cationic lipid, virosome or liposome), and a target cell specific binding agent (e.g., a ligand recognized by target cell specific receptor). Preferred complexes must be sufficiently stable in vivo to prevent significant uncoupling prior to internalization by the target cell; however, these complexes can be cleavable under appropriate circumstances such that the ODN can be released in a functional form.

Pharmacological Composition

The present inventive pharmacological composition comprises the present inventive ODN and a pharmacologically acceptable carrier. Pharmacologically acceptable carriers (e.g., physiologically or pharmaceutically acceptable carriers) are well known in the art.

The present inventive pharmacological composition facilitates the use of the present inventive ODN, both in vivo and ex vivo. Such a composition can be suitable for delivery of the active ingredient to any suitable host, such as a patient for medical application, and can be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmacological compositions for use in accordance with the present invention can be formulated in a conventional manner using one or more pharmacologically (e.g., physiologically or pharmaceutically) acceptable carriers comprising excipients, as well as optional auxiliaries that facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Thus, for injection, the active ingredient can be formulated in aqueous solutions, preferably in physiologically compatible buffers. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. For oral administration, the active ingredient can be combined with carriers suitable for inclusion into tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like. For administration by inhalation, the active ingredient is conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant. The active ingredient can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Such compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Other pharmacological excipients are known in the art.

Method of Inducing an Immune Response

The present inventive method of inducing an immune response comprises administering the present inventive ODN to a host in order to induce an immune response in the host.

Administration of the present inventive ODN can be by any suitable method. For example, the ODN can be administered in vivo or ex vivo. Preferably, the ODN is administered in vivo to a mammal, particularly a human. Optionally, the ODN can be contained within or conjugated with a protein, hydrocarbon or lipid. Once this molecule is administered, the ODN sequence must be exposed on the surface to induce an immune response. The ODN can also be co-administered with a protein, hydrocarbon, or lipid. Co-administration can be such that the ODN is administered before, at substantially the same time as, or after the protein, hydrocarbon, or lipid. Preferably, the ODN is administered at substantially the same time as the protein, hydrocarbon, or lipid.

After administration of the novel ODNs, while not intending to be bound by any particular theory, it is thought that the ODNs initially act on antigen presenting cells (e.g., macrophages and dendritic cells). These cells then release cytokines, which activate natural killer (NK) cells. Either a cell-mediated or humoral immune response then occurs in the host.

The cell-mediated or local immune response is produced by T cells, which are able to detect the presence of invading pathogens through a recognition system referred to as the T-cell antigen receptor. Upon detection of an antigen, T cells direct the release of multiple T-cell cytokines, including IL-2, IL-3, IFN-γ, TNF-β, GM-CSF and high levels of TNF-α, and chemokines MIP-1α, MIP-1β, and RANTES. IL-2, is a T-cell growth factor that promotes the production of additional T cells sensitive to the particular antigen. This production constitutes a clone of the T cells. The sensitized T cells attach to cells containing the antigen. T cells carry out a variety of regulatory and defense functions and play a central role in immunologic responses. When stimulated to produce a cell-mediated immune response, some T cells respond by acting as killer cells, killing the host's own cells when these cells are infected or cancerous and therefore recognized as foreign. Some T cells respond by stimulating B cells, while other T cells respond by suppressing immune response. Preferably, if a cell-mediated immune response is induced, non-B cells are activated, more preferably, cytokines are produced, and most preferably, IFN-γ is produced.

The humoral or systemic immune response depends on the ability of the B cells to recognize specific antigens. The mechanism by which B cells recognize antigens is through specific receptors on the surface of the B cells. When an antigen attaches to the receptor site of a B cell, the B cell is stimulated to divide. The daughter cells become plasma cells that manufacture antibodies complementary to the attached antigen. Each plasma cell produces thousands of antibody molecules per minute, which are released into the bloodstream. Many B cells appear to be regulated by the helper T cells and suppressor T cells and produce various cytokines, e.g., IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, GM-CSF and low levels of TNF-α. Helper T cells stimulate B cells to produce antibodies against antigens, while suppressor T cells inhibit antibody production. Some B cells, however, are T-cell independent and require no stimulation by the T cells. Preferably, if a humoral immune response is induced, B cells are activated, more preferably, IL-6, is produced, and most preferably, antibodies are produced.

In addition, induction of one type of immune response may allow for immune regulation because up regulation of one type of immune response may down regulate the other type of immune response. This immune regulation allows for customizing or tailoring of the type of immune response when administering an ODN.

The present inventive method can be used to treat, prevent, or ameliorate any suitable allergic reaction in combination with any suitable anti-allergenic agent. An allergy, in the context of the present invention, refers to an acquired hypersensitivity to a substance (i.e., an allergen). Allergic conditions include eczema, allergic rhinitis or coryza, hay fever, bronchial asthma, uticaria (hives), food allergies, and other atopic conditions. The list of allergens is extensive and includes pollens, insect venoms, animal dander, dust, fungal spores, and drugs (e.g., penicillin). Examples of natural, animal, and plant allergens can be found in International Patent Application WO 98/18810. Preferably, the present inventive method is used to treat allergic asthma. Suitable anti-allergenic agents include those substances given in treatment of the various allergic conditions described above, examples of which can be found in the Physicians' Desk Reference (1998).

The present inventive method can be used to treat any suitable cancer in combination with any suitable anti-cancer agent. Suitable cancers include cancers of the brain, lung (e.g., small cell and non-small cell), ovary, breast, prostate, and colon, as well as carcinomas and sarcomas. Preferably, the present inventive method is used to treat a solid tumor cancer. Suitable anti-cancer agents include those substances given in treatment of the various conditions described above, examples of which can be found in the Physicians' Desk Reference (1998).

The present inventive method can be used to improve the efficacy of any suitable vaccine. Suitable vaccines include those directed against Hepatitis A, B, and C, examples of which can be found in the Physicians' Desk Reference (1998), and DNA vaccines directed against HIV and malaria. See generally D. Klinman et al., CpG Motifs as Immune Adjuvants, 17 Vaccine 19 (1999); M. J. McCluskie and H. L. Davis, CpG DNA is a Potent Enhancer of Systemic & Mucosal Immune Response Against Hepatitis B Surface Antigen with Intra-Nasal Administration to Mice, 161 J. Immun. 4463 (1998).

The present inventive method can be used to treat, prevent, or ameliorate any suitable disease associated with the immune system. Preferred diseases associated with the immune system are autoimmune disorders and immune system deficiencies, e.g., lupus erythematosus, and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Immune system deficiencies include those diseases or disorders in which the immune system is not functioning at normal capacity, or in which it would be useful to boost the immune system response.

The present inventive method can be used to treat, prevent, or ameliorate any suitable infection in combination with any suitable anti-infectious agent. Examples include francisella, schistosomiasis, tuberculosis, AIDS, malaria, and leishmania. Examples of suitable infectious viruses, bacteria, fungi, and other organisms (e.g., protists) can be found in International Patent Application WO 98/18810. Suitable anti-infectious agents include those substances given in treatment of the various conditions described elsewhere, examples of which can be found in the Physicians' Desk Reference (1998).

The present inventive method can be used to treat, prevent, or ameliorate the symptoms resulting from exposure to a bio-warfare agent. Suitable bio-warfare agents include those naturally occurring biological agents that have been specifically modified in the laboratory. Often, modification of these agents has altered them such that there is no known treatment. Examples include Ebola, Anthrax, and Listeria. In the course of ameliorating the symptoms after exposure, use of the present inventive ODNs may not cure the patient, but rather can extend the patient's life sufficiently such that some other treatment can then be applied.

The present invention is further described in the following examples. These examples are intended only to illustrate the invention and are not intended to limit the scope of the invention in any way.

EXAMPLESExample 1

The following example demonstrates induction of an immune response by various ODNs. Induction was measured by production of the cytokines IL-6 and TNF-γ, and cell proliferation.

IL-6 levels and cell proliferation are set forth in Table 1: Induction of a Humoral Immune Response In Vitro. These data demonstrate that a sequence containing 5′ N1N2N3T-CpG-WN4N5N6 3′, wherein the central CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are any nucleotides, is desirable to induce a humoral immune response. In addition, maximum induction was observed for ODNs that contained a phosphorothioate backbone. IFN-γ levels and cell proliferation are set forth in Table 2: Induction of a Cell-Mediated Immune Response In Vitro. These data demonstrate that a sequence containing 5′ RY-CpG-RY 3′, wherein the central CpG motif is unmethylated, R is A or G and Y is C or T, is desirable to induce a cell-mediated immune response. Maximum induction occurred with ODNs containing phosphodiesterase linkages.

TABLE 1

Induction of a Humoral Immune Response In Vitro.

IL-6 Levels

Cell Proliferation

(ELISA)

(3H Thymidine Incorporation)

SEQ ID NO: 1

65

52

SEQ ID NO: 2

85

44

SEQ ID NO: 3

54

50

SEQ ID NO: 4

48

61

SEQ ID NO: 5

42

100

SEQ ID NO: 6

55

23

SEQ ID NO: 7

35

69

SEQ ID NO: 8

28

38

SEQ ID NO: 9

41

20

SEQ ID NO: 10

42

16

SEQ ID NO: 11

33

77

SEQ ID NO: 12

25

13

SEQ ID NO: 13

28

13

SEQ ID NO: 14

35

67

SEQ ID NO: 15

28

54

SEQ ID NO: 16

39

50

SEQ ID NO: 17

50

32

SEQ ID NO: 18

26

1

SEQ ID NO: 19

12

2

SEQ ID NO: 20

55

92

SEQ ID NO: 21

53

26

SEQ ID NO: 22

8

2

SEQ ID NO: 23

12

1

SEQ ID NO: 24

14

0

SEQ ID NO: 25

30

42

SEQ ID NO: 26

43

60

SEQ ID NO: 27

17

15

SEQ ID NO: 28

14

0

SEQ ID NO: 29

10

1

SEQ ID NO: 30

28

23

SEQ ID NO: 31

16

17

TABLE 2

Induction of a Cell-Mediated Immune Response In Vitro.

IFN-γ Levels

Cell Proliferation

(ELISA)

(3H Thymidine Incorporation)

SEQ ID NO: 32

78

1

SEQ ID NO: 33

100

2

SEQ ID NO: 34

73

2

SEQ ID NO: 35

88

4

SEQ ID NO: 36

81

5

SEQ ID NO: 37

45

4

SEQ ID NO: 38

78

0

SEQ ID NO: 39

33

5

SEQ ID NO: 40

68

2

SEQ ID NO: 41

54

2

SEQ ID NO: 42

54

1

SEQ ID NO: 43

74

4

SEQ ID NO: 44

53

4

SEQ ID NO: 45

32

9

SEQ ID NO: 46

24

1

SEQ ID NO: 47

23

8

SEQ ID NO: 48

22

25

SEQ ID NO: 49

34

26

SEQ ID NO: 50

36

8

SEQ ID NO: 51

24

17

SEQ ID NO: 52

21

9

SEQ ID NO: 53

19

2

SEQ ID NO: 54

12

8

SEQ ID NO: 55

15

5

SEQ ID NO: 56

22

6

SEQ ID NO: 57

18

3

SEQ ID NO: 58

18

6

SEQ ID NO: 59

12

21

SEQ ID NO: 60

13

4

SEQ ID NO: 61

—

2

SEQ ID NO: 62

12

23

SEQ ID NO: 63

16

1

SEQ ID NO: 64

16

4

SEQ ID NO: 65

19

2

SEQ ID NO: 66

16

4

SEQ ID NO: 67

14

2

SEQ ID NO: 68

13

1

SEQ ID NO: 69

12

2

SEQ ID NO: 70

19

2

SEQ ID NO: 71

13

1

SEQ ID NO: 72

14

46

SEQ ID NO: 73

—

4

SEQ ID NO: 74

16

1

SEQ ID NO: 75

24

1

SEQ ID NO: 76

13

1

SEQ ID NO: 77

12

1

SEQ ID NO: 78

13

1

SEQ ID NO: 79

13

1

SEQ ID NO: 80

12

1

SEQ ID NO: 81

14

20

SEQ ID NO: 82

14

43

SEQ ID NO: 83

14

1

SEQ ID NO: 84

12

1

SEQ ID NO: 85

15

2

SEQ ID NO: 86

13

1

SEQ ID NO: 87

12

0

SEQ ID NO: 88

—

3

SEQ ID NO: 89

15

1

SEQ ID NO: 90

18

2

SEQ ID NO: 91

13

2

SEQ ID NO: 92

12

1

SEQ ID NO: 93

14

2

SEQ ID NO: 94

14

1

SEQ ID NO: 95

44

3

SEQ ID NO: 96

24

1

SEQ ID NO: 97

21

6

SEQ ID NO: 98

36

38

SEQ ID NO: 99

21

26

The foregoing data demonstrates the induction of an immune response in human cells, as exemplified by PBMC, and as measured by the production of the cytokines IFN-γ and IL-6, and cell proliferation, occurs upon the administration of various ODNs.

Example 2

The following example demonstrates induction of an immune response ex vivo by various ODNs. Induction was measured by production of the cytokine IL-6.

A human B cell line (RPMI 8226) was maintained according to the manufacturers recommendations. ODNs were synthesized as described in Example 1. In some ODNs, the normal DNA phosphodiesterase linkages were replaced with phosphorothioate linkages, as described in Example 1. To reduce degradation of the ODNs, those that did not have an entire phosphorothioate backbone contained phosphorothioate linkages at the ends. The cells were incubated with various ODNs for 14 hrs. IL-6 production was determined by ELISA using anti-IL-6 antibodies, as described in Example 1.

IL-6 levels are set forth in Table 3:, Induction of a Humoral Immune Response Ex Vivo. These data confirm that a sequence containing 5′ N1N2N3T-CpG-WN4N5N6 3′, which are linked by phosphorothioate bonds and wherein the central CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are any nucleotides, is desirable to induce a humoral immune response.

TABLE 3

Induction of a Humoral Immune Response Ex Vivo.

IL-6 Levels (ELISA)

SEQ ID NO: 1

100

SEQ ID NO: 2

89

SEQ ID NO: 3

85

SEQ ID NO: 4

82

SEQ ID NO: 5

82

SEQ ID NO: 6

78

SEQ ID NO: 7

78

SEQ ID NO: 8

78

SEQ ID NO: 9

73

SEQ ID NO: 10

65

SEQ ID NO: 11

62

SEQ ID NO: 12

58

SEQ ID NO: 13

57

SEQ ID NO: 14

56

SEQ ID NO: 15

50

SEQ ID NO: 16

48

SEQ ID NO: 17

47

SEQ ID NO: 18

45

SEQ ID NO: 19

40

SEQ ID NO: 20

39

SEQ ID NO: 21

33

SEQ ID NO: 22

25

SEQ ID NO: 23

23

SEQ ID NO: 24

21

SEQ ID NO: 25

18

SEQ ID NO: 26

17

SEQ ID NO: 27

17

SEQ ID NO: 28

16

SEQ ID NO: 29

16

SEQ ID NO: 30

13

SEQ ID NO: 31

13

The foregoing data demonstrates the induction of an immune response in human cells, as exemplified by the human B cell line RPMI 8226, and as measured by production of the cytokine IL-6, occurs upon administration of various ODNs.

The following table lists additional ODNs which fall within the scope of the present invention.

TABLE 4

SEQ ID NO: 100

SEQ ID NO: 101

SEQ ID NO: 102

SEQ ID NO: 103

SEQ ID NO: 104

SEQ ID NO: 105

SEQ ID NO: 106

SEQ ID NO: 107

SEQ ID NO: 108

SEQ ID NO: 109

SEQ ID NO: 110

SEQ ID NO: 111

SEQ ID NO: 112

SEQ ID NO: 113

SEQ ID NO: 114

SEQ ID NO: 115

SEQ ID NO: 116

SEQ ID NO: 117

SEQ ID NO: 118

SEQ ID NO: 119

SEQ ID NO: 120

SEQ ID NO: 121

SEQ ID NO: 122

SEQ ID NO: 123

SEQ ID NO: 124

SEQ ID NO: 125

SEQ ID NO: 126

SEQ ID NO: 127

SEQ ID NO: 128

SEQ ID NO: 129

SEQ ID NO: 130

SEQ ID NO: 131

SEQ ID NO: 132

SEQ ID NO: 133

SEQ ID NO: 134

SEQ ID NO: 135

SEQ ID NO: 136

SEQ ID NO: 137

SEQ ID NO: 138

SEQ ID NO: 139

SEQ ID NO: 140

SEQ ID NO: 141

SEQ ID NO: 142

SEQ ID NO: 143

All of the references cited herein, including patents, patent applications, and publications, are hereby incorporated in their entireties by reference.

While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments may be used and it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.

Claims (23)

What is claimed is:

1. A substantially pure or isolated synthetic oligodeoxynucleotide, wherein the oligodeoxynucleotide comprises the nucleic acid sequence set forth as SEQ ID NO: 22, and wherein the oligodeoxynucleotide is 100 nucleotides or less in length.

2. The synthetic oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide is modified to prevent degradation.

3. The synthetic oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide has a phosphate backbone modification.

5. The synthetic oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide is 20 nucleotides in length.

6. The synthetic oligodeoxynucleotide claim 1, wherein the oligodeoxynucleotide is 50 nucleotides or less in length.

7. The synthetic oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide is 30 nucleotides or less in length.

8. An oligodeoxynucleotide delivery complex comprising the synthetic oligodeoxynucleotide of claim 4 and a targeting means.

9. The oligodeoxynucleotide delivery complex of claim 8, wherein the targeting means is selected from the group consisting of cholesterol, virosome, liposome, lipid, and a target cell specific binding agent.

10. A composition comprising the synthetic oligodeoxynucleotide of claim 1 and a pharmacologically acceptable carrier.

11. A method of inducing cytokine production by a peripheral blood mononuclear cell, comprising contacting the peripheral blood mononuclear cell with an effective amount of the synthetic oligodexoynucleotide of claim 1, thereby inducing the production of the cytokine, wherein the cytokine is interleukin (IL)-6 or interferon γ.

12. The method of claim 11, wherein the synthetic oligodeoxynucleotide is 30 nucleotides or less in length.

13. The method of claim 11, wherein the synthetic oligodeoxynucleotide consists of the nucleic acid sequence set forth as SEQ ID NO: 22.

14. The method of claim 11, wherein the synthetic oligodeoxynucleotide is modified to prevent degradation.

15. The method of claim 11, wherein the synthetic oligodeoxynucleotide has a phosphate backbone modification.

16. The method of claim 15, wherein the phosphate backbone modification is a phosphorothioate backbone modification.

17. The method of claim 11, wherein the synthetic oligodeoxynucleotide is 50 nucleotides or less in length.

18. The method of claim 11, wherein the peripheral blood mononuclear cell is a B cell, and wherein the cytokine is IL-6.